International Standards for Tuberculosis Care: revisiting the cornerstones of tuberculosis care and control

Size: px
Start display at page:

Download "International Standards for Tuberculosis Care: revisiting the cornerstones of tuberculosis care and control"

Transcription

1 Special Report International Standards for Tuberculosis Care: revisiting the cornerstones of tuberculosis care and control Elizabeth Fair, Philip C Hopewell and Madhukar Pai CONTENTS Tuberculosis remains a global challenge International Standards for Tuberculosis Care Differing contexts, similar challenges, a shared approach Information resources Key issues References Affiliations Tuberculosis (TB) remains an enormous global health problem. There are 8 9 million new cases and 2 million deaths from TB annually. Despite the overwhelming burden of disease, the basic principles of care for persons with, or suspected of having, TB are the same worldwide: a diagnosis should be established promptly and accurately, standardized treatment regimens of proven efficacy should be used together with appropriate treatment support and supervision, the response to treatment should be monitored, and the essential public health responsibilities must be carried out. As an approach to improving the care of patients with TB, an evidence-based document, the International Standards for Tuberculosis Care (ISTC) was developed and has been endorsed by more than 30 international and national agencies. This special report introduces the ISTC and discusses the fact that accurate diagnosis and effective treatment are not only essential for good patient care, they are the key elements in the public health response to TB and are the cornerstone of TB control. With the recent emergence of extensively drug-resistant TB, there is an urgent need to ensure globally that standards of TB care are based on rigorous scientific findings, are clear and well understood, and are accessible to and applied by all types of healthcare providers in all corners of the world. Author for correspondence McGill University, Department of Epidemiology, Biostatistics and Occupational Health, 1020 Pine Avenue West, Montreal, Quebec, H3A 1A2, Canada Tel.: Fax: madhukar.pai@mcgill.ca KEYWORDS guidelines, recommendations, standards, tuberculosis Expert Rev. Anti Infect. Ther. 5(1), (2007) Tuberculosis remains a global challenge Although in the past 10 years there has been substantial progress in the development and implementation of the strategies necessary for effective tuberculosis control, the disease remains an enormous and growing global health problem [1 4]. A third of the world s population is infected with Mycobacterium tuberculosis, with 95% of cases occuring in developing countries [3]. In 2003, there were an estimated 8.8 million new cases of tuberculosis, of which 3.9 million were sputum smearpositive and, thus, highly infectious [1,2]. The number of tuberculosis cases that occur in the world each year is still growing, although the rate of increase is slowing. In the African region of the WHO, the tuberculosis case rate continues to increase, owing to both the epidemic of HIV infection in sub-saharan countries and the poor or absent primary-care services throughout the region [1,2]. In many other countries, owing to incomplete application of effective care and control measures, tuberculosis case rates are either stagnant or decreasing more slowly than expected. The failure to bring about a more rapid reduction in tuberculosis incidence is related, at least in part, to a failure to fully engage all medical care providers in the delivery of high-quality care, in coordination with local and national tuberculosis control programs. In many parts of the world, private practitioners are involved in the diagnosis and treatment of tuberculosis [5 8]. Traditional healers, general, specialist and academic physicians, nurses, unlicensed practitioners, physicians in private practice, practitioners of alternative medicine and community organizations, / Future Drugs Ltd ISSN

2 Fair, Hopewell & Pai among others, all play roles in tuberculosis care and, therefore, in tuberculosis control. Little is known regarding the adequacy of care delivered by private providers; however, available data suggest that, in many instances, the services are of poor quality. A global situation assessment reported by the WHO, as well as other studies conducted during the past years, demonstrates that clinicians who work in the private healthcare sector often deviate from standard, internationally recommended tuberculosis management practices [6,7]. These deviations include: under-utilization of sputum microscopy for diagnosis, generally associated with over-reliance on radiography; use of nonrecommended drug regimens, with incorrect combinations of drugs and mistakes in both drug dosage and duration of treatment; and failure to supervise and assure adherence to treatment [6,7,9 15]. Anecdotal evidence also suggests that there is an over-reliance on poorly validated or inappropriate diagnostic tests, such as serological assays, often in preference to conventional bacteriological evaluations. Together, these findings highlight flaws in healthcare practices that lead to substandard tuberculosis care for populations that are most vulnerable to the disease and are least able to bear the consequences of such systemic failures. International Standards for Tuberculosis Care The basic principles of care for individuals with, or suspected of having, tuberculosis are the same worldwide: a diagnosis should be established promptly and accurately; standardized treatment regimens of proven efficacy should be used, together with appropriate treatment support and supervision; the response to treatment should be monitored; and the essential public health responsibilities must be carried out. Accurate diagnosis and effective treatment are not only essential for good patient care, they are the key elements in the public health response to tuberculosis and are the cornerstone of tuberculosis control. Substandard care will result in poor patient outcomes, continued infectiousness with transmission of M. tuberculosis to others and generation and propagation of drug resistance. As an approach to improving the care of patients with tuberculosis, the principles noted above were used as the foundation for a set of evidence-based standards, the International Standards for Tuberculosis Care (ISTC), which was released on World TB Day 2006 [16] and subsequently published in a condensed form in Lancet Infectious Diseases [17]. Since its release, the ISTC has been endorsed by more than 30 international and national agencies and organizations, including the WHO, the Stop TB Partnership, the International Union against TB and Lung Disease (IUATLD), the American Thoracic Society (ATS), the CDC, the International Council of Nurses, the Canadian Tuberculosis Committee and the World Care Council. The ISTC was developed by examining existing evidence and, where evidence was lacking, conducting rigorous systematic reviews. The result was agreement on a group of 17 standards: six addressing diagnosis, nine addressing treatment and two addressing public health responsibilities (TABLE 1). The ISTC as a whole is not meant to be a guidance document for how tuberculosis care should be provided but rather the principles and foundation on which guidelines can be based. The document emphasizes that any clinician who provides services for tuberculosis is assuming an important public health function. Differing contexts, similar challenges, a shared approach There is a vast spectrum of diagnostic, treatment and public health practices involved in tuberculosis care. The ISTC presents the essential elements of tuberculosis care and, consequently, should be viewed as a platform on which additional elements of care can be based. In many geographical areas, the available facilities and resources exceed those required to comply with the ISTC. However, even in these areas, certain elements of the standards may not be implemented. This is particularly true with regards to treatment supervision and the application of a true patient-centered approach, as specified in the ISTC. Conversely, healthcare providers from settings in which there is no regular access to vital services, such as chest radiographic examinations or drug-sensitivity testing, will recognize that they are far from able to achieve the practices recommended in the ISTC. For example, in a rural clinic in Tanzania, basic diagnostic techniques, such as sputum smear microscopy, may be a challenge owing to lack of a microscope, lack of stain or slides, or lack of electricity. In the context of such diversity, the ISTC can function as a template or checklist against which providers and programs can assess the realities of their particular situations and determine what is needed to bring practices up to the level of those specified by the ISTC. In both areas with adequate resources and in resource-constrained settings, the ISTC provides a starting point to determine what is needed a tool for a situational analysis that can then be used to guide pursuit of improved tuberculosis care. Using this standardized situational analysis as a point of departure, specific plans can be developed that, for example, may be focused on increasing funding, developing new systems or altering approaches so as to be consistent with the ISTC, with the goal of providing high-quality tuberculosis care that meets the needs of all patients. In the last few months, a new threat has been identified: extensively drug-resistant tuberculosis (XDR-TB) [18]. Currently, the WHO defines XDR-TB as tuberculosis resistant to at least rifampicin and isoniazid from among the first-line antituberculosis drugs (which is the definition of multidrug resistant [MDR]-TB) in addition to any fluoroquinolones, and to at least one of three injectable second-line antituberculosis drugs used in tuberculosis treatment (capreomycin, kanamicin and amikacin). What is evident is that had care of the quality specified in the ISTC been applied in the areas where XDR-TB is emerging, this disaster would not have happened. The emergence of XDR-TB is a sign that proper standards of tuberculosis care are far from being applied universally [19]. It is worth looking back at what the tuberculosis community learned from the experience of New York City (NY, USA) just over 10 years ago. In the early 1990s, there was a significant 62 Expert Rev. Anti Infect. Ther. 5(1), (2007)

3 International Standards for Tuberculosis Care Table 1. International Standards for Tuberculosis Care. Standards for diagnosis Standard 1 All persons with otherwise unexplained productive cough lasting 2 3 weeks should be evaluated for TB Standard 2 Standard 3 Standard 4 Standard 5 Standard 6 All patients (adults, adolescents and children who are capable of producing sputum) suspected of having pulmonary TB should have at least two, and preferably three, sputum specimens obtained for microscopic examination. When possible, at least one early morning specimen should be obtained For all patients (adults, adolescents and children) suspected of having extrapulmonary TB, appropriate specimens from the suspected sites of involvement should be obtained for microscopy and, where facilities and resources are available, for culture and histopathological examination All persons with chest radiographical findings suggestive of TB should have sputum specimens submitted for microbiological examination The diagnosis of sputum smear-negative pulmonary TB should be based on the following criteria: at least three negative sputum smears (including at least one early morning specimen); chest radiography findings consistent with TB; and lack of response to a trial of broad-spectrum antimicrobial agents. (Since fluoroquinolones are active against Mycobacterium tuberculosis complex and, thus, may cause transient improvement in persons with TB, they should be avoided). For such patients, if facilities are available, sputum cultures should be obtained. In individuals with known or suspected HIV infection, the diagnostic evaluation should be expedited The diagnosis of intrathoracic (i.e., pulmonary, pleural and mediastinal or hilar lymph node) TB in symptomatic children with negative sputum smears should be based on the finding of chest radiographical abnormalities consistent with TB and either a history of exposure to an infectious case or evidence of TB infection (positive tuberculin skin test or interferon-γ release assay). For such patients, if facilities for culture are available, sputum specimens should be obtained (by expectoration, gastric washings or induced sputum) for culture Standards for treatment Standard 7 Any practitioner treating a patient for TB is assuming an important public health responsibility. To fulfill this responsibility, the practitioner must not only prescribe an appropriate regimen, but also be capable of assessing the adherence of the patient to the regimen and addressing poor adherence when it occurs. By so doing, the provider will be able to ensure adherence to the regimen until treatment is completed Standard 8 Standard 9 Standard 10 Standard 11 All patients (including those with HIV infection) who have not been treated previously should receive an internationally accepted first-line treatment regimen using drugs of known bioavailability. The initial phase should consist of 2 months of isoniazid, rifampicin, pyrazinamide and ethambutol. The preferred continuation phase consists of isoniazid and rifampicin administered for 4 months. Isoniazid and ethambutol administered for 6 months is an alternative continuation-phase regimen that may be used when adherence cannot be assessed, but it is associated with a higher rate of failure and relapse, especially in patients with HIV infection. The doses of anti-tb drugs used should conform to international recommendations. Fixed dose combinations of two (isoniazid and rifampicin), three (isoniazid, rifampicin and pyrazinamide) and four (isoniazid, rifampicin, pyrazinamide and ethambutol) drugs are highly recommended, especially when medication ingestion is not observed To foster and assess adherence, a patient-centered approach to the administration of drug treatment, based on the patient s needs and mutual respect between the patient and the provider, should be developed for all patients. Supervision and support should be sex sensitive and age specific and should draw on the full range of recommended interventions and available support services, including patient counseling and education. A central element of the patient-centered strategy is the use of measures to assess and promote adherence to the treatment regimen and to address poor adherence when it occurs. These measures should be tailored to the individual patient s circumstances and be mutually acceptable to the patient and the provider. Such measures may include direct observation of medication ingestion (DOT) by a treatment supporter who is acceptable and accountable to the patient and the health system All patients should be monitored for response to therapy, best judged in patients with pulmonary TB by follow-up sputum microscopy (two specimens) at least at the time of completion of the initial phase of treatment (2 months), at 5 months and at the end of treatment. Patients who have positive smears during the 5th month of treatment should be considered as treatment failures and have therapy modified appropriately (see standards 14 and 15). In patients with extrapulmonary TB and in children, the response to treatment is best assessed clinically. Follow-up radiographical examinations are usually unnecessary and may be misleading A written record of all medications given, bacteriological response and adverse reactions should be maintained for all patients Taken from [16,17]. DOT: Directly observed therapy; MDR: Multidrug resistant; TB: Tuberculosis. 63

4 Fair, Hopewell & Pai Table 1. International Standards for Tuberculosis Care (cont.). Standard 12 Standard 13 Standard 14 Standard 15 In areas with a high prevalence of HIV infection in the general population and where TB and HIV infection are likely to coexist, HIV counseling and testing are indicated for all TB patients as part of their routine management. In areas with lower prevalence rates of HIV, HIV counseling and testing are indicated for TB patients with symptoms and/or signs of HIV-related conditions and in TB patients with a history suggestive of high risk of HIV exposure All patients with TB and HIV infection should be evaluated to determine whether antiretroviral therapy is indicated during the course of treatment for TB. Appropriate arrangements for access to antiretroviral drugs should be made for patients who meet indications for treatment. Given the complexity of co-administration of anti-tb treatment and antiretroviral therapy, consultation with a physician who is expert in this area is recommended before initiation of concurrent treatment for tuberculosis and HIV infection, regardless of which disease appeared first. However, initiation of treatment for TB should not be delayed. Patients with TB and HIV infection should also receive cotrimoxazole as prophylaxis for other infections An assessment of the likelihood of drug resistance, based on history of prior treatment, exposure to a possible source case having drug-resistant organisms, and the community prevalence of drug resistance should be obtained for all patients. Patients who fail treatment and chronic cases should always be assessed for possible drug resistance. For patients in whom drug resistance is considered to be likely, culture and drug susceptibility testing for isoniazid, rifampicin and ethambutol should be performed promptly Patients with TB caused by drug-resistant (especially MDR) organisms should be treated with specialized regimens containing second line anti-tb drugs. At least four drugs to which the organisms are known or presumed to be susceptible should be used and treatment should be given for 18 months. Patient-centered measures are required to ensure adherence. Consultation with a provider experienced in treatment of patients with MDR-TB should be obtained Standards for public health responsibilities Standard 16 All providers of care for patients with TB should ensure that individuals (especially children aged <5 years and individuals with HIV infection) who are in close contact with patients who have infectious TB are evaluated and managed in line with international recommendations. Children aged below 5 years and individuals with HIV infection who have been in contact with an infectious case should be evaluated for both latent infection with M. tuberculosis and for active TB Standard 17 All providers must report both new and retreatment TB cases and their treatment outcomes to local public health authorities, in conformance with applicable legal requirements and policies Taken from [16,17]. DOT: Directly observed therapy; MDR: Multidrug resistant; TB: Tuberculosis. resurgence of tuberculosis and the emergence of a highly resistant MDR-TB strain (the W strain) of M. tuberculosis in New York City. As the incidence of tuberculosis had declined over the years, so had the investment in the programs that controlled the disease. This gradual divestment in public health, coupled with the HIV epidemic, led to a resurgence of tuberculosis. By 1992, the number of cases had nearly tripled in 15 years [20]. In the first quarter of 1991, New York City, comprising only 3% of the nation s population, accounted for 61% of the MDR-TB cases in the USA [21]. In some neighborhoods of the city, incidence rates were estimated to be 222 per 100,000, greater than in many developing countries [22]. When these trends were identified, there was great alarm in the public health community and attention was refocused on the basic standards of care for tuberculosis. Within 2 years, there was a dramatic decrease in the disease. Incidence rates were cut by 20%, and there was interruption of ongoing transmission of tuberculosis. Simple programmatic interventions and planning, such as directly observed therapy, improved case detection and infection control, and broader use of drug susceptibility testing were identified as having contributed to reversing the trend. The costs borne by the public health system in New York City were extraordinary, yet the primary interventions relatively simple. Many of these interventions are the tenets of the ISTC. As we face this new threat of XDR-TB, it is imperative to revisit the cornerstones of tuberculosis care. Without diligent attention, we may see further spread of XDR-TB and this will become a serious challenge to health systems, regardless of the setting and resources. Now more than ever, we need to ensure globally that our standards of care are based on rigorous scientific findings, are clear and well understood, and are accessible to and applied by all types of health care providers public, private, certified and nontraditional in all corners of the world. Ultimately, new drugs and new diagnostics are needed, but while these work their way through the pipeline it is imperative to universally implement the essential standards of tuberculosis care. Information resources The International Standards for Tuberculosis Care report can be freely downloaded from several websites: Stop TB report.pdf The WHO The abbreviated publication [17] can be downloaded freely from the Lancet website 64 Expert Rev. Anti Infect. Ther. 5(1), (2007)

5 International Standards for Tuberculosis Care Key issues The basic principles of care for individuals with, or suspected of having, tuberculosis (TB) are the same worldwide. Accurate diagnosis and effective treatment of TB are essential for good patient care, and are key elements in the public health response to and control of TB. Incomplete and/or inadequate TB care poses a threat to the continued spread of the disease and the propagation of drug-resistant TB. There is considerable evidence that quality of TB care varies widely, and substandard care is widespread, especially in the private healthcare sector in many developing countries. As an approach to engaging all healthcare providers, and improving the care of patients with TB, a set of evidence-based standards, the International Standards for Tuberculosis Care (ISTC), were developed and released on World TB Day To improve the quality of TB care, the ISTC should be understandable, accessible and universally applied by all care providers public, private, certified and nontraditional. References 1 WHO, Global Tuberculosis Control. Surveillance, planning, financing. WHO Report. WHO, Geneva, (2005). 2 Corbett EL, Watt CJ, Walker N et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163(9), (2003). 3 Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282(7), (1999). 4 Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293(22), (2005). 5 Uplekar M. Involving private health care providers in delivery of TB care: global strategy. Tuberculosis (Edinb.) 83(1 3), (2003). 6 Uplekar M, Pathania V, Raviglione M. Private practitioners and public health: weak links in tuberculosis control. Lancet 358(9285), (2001). 7 WHO. Involving private practitioners in tuberculosis control: issues, interventions, and emerging policy framework. WHO, Geneva, Switzerland 1 81 (2001). 8 WHO. Public-private mix for DOTS. Practical tools to help implementation. WHO, Geneva, Switzerland (2003). 9 Lonnroth K, Thuong LM, Linh PD, Diwan VK. Delay and discontinuity a survey of TB patients search of a diagnosis in a diversified health care system. Int. J. Tuberc. Lung Dis. 3(11), (1999). 10 Olle-Goig JE, Cullity JE, Vargas R. A survey of prescribing patterns for tuberculosis treatment amongst doctors in a Bolivian city. Int. J. Tuberc. Lung Dis. 3(1), (1999). 11 Prasad R, Nautiyal RG, Mukherji PK, Jain A, Singh K, Ahuja RC.. Diagnostic evaluation of pulmonary tuberculosis: what do doctors of modern medicine do in India? Int. J. Tuberc. Lung Dis. 7(1), (2003). 12 Shah SK, Sadiq H, Khalil M et al. Do private doctors follow national guidelines for managing pulmonary tuberculosis in Pakistan? East Mediterr. Health J. 9(4), (2003). 13 Singla N, Sharma PP, Singla R, Jain RC. Survey of knowledge, attitudes and practices for tuberculosis among general practitioners in Delhi, India. Int. J. Tuberc. Lung Dis.. 2(5), (1998). 14 Suleiman BA, Houssein AI, Mehta F, Hinderaker SG. Do doctors in north-western Somalia follow the national guidelines for tuberculosis management? East Mediterr. Health J. 9(4), (2003). 15 Uplekar MW Shepard DS. Treatment of tuberculosis by private general practitioners in India. Tubercle 72(4), (1991). 16 International Standards for Tuberculosis Care (ISTC). Tuberculosis Coalition for Technical Assistance, The Hague, Holland (2006). 17 Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect. Dis. 6(11), (2006). 18 Raviglione M. XDR-TB: entering the postantibiotic era? Int. J. Tuberc. Lung Dis.. 10(11), (2006). 19 The tuberculosis X factor. Lancet Infect. Dis. 6(11), 679 (2006). 20 Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City turning the tide. N. Engl. J. Med. 333(4), (1995). 21 Bloch AB, Cauthen GM, Onorato IM et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 271(9), (1994). 22 Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during Bull. World Health Organ. 72(2), (1994). Affiliations Elizabeth Fair, PhD, MPH University of California, Francis J Curry National Tuberculosis Center, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, San Francisco, CA 94110, USA Tel.: Fax: efair@globalhealth.ucsf.edu Philip C Hopewell, MD University of California, Francis J Curry National Tuberculosis Center, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, San Francisco, CA 94110, USA Tel.: Fax: phopewell@medsfgh.ucsf.edu Madhukar Pai, MD, PhD Assistant Professor, McGill University, Department of Epidemiology, Biostatistics and Occupational Health, 1020 Pine Avenue West, Montreal, Quebec, H3A 1A2, Canada Tel.: Fax: madhukar.pai@mcgill.ca 65

11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction

11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction SECOND EDITION 2009 Madhukar Pai McGill University Introduction 1 Purpose of ISTC ISTC Version 2: Key Points 21 Standards Differ from existing guidelines: standards present what should be done, whereas,

More information

International Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007

International Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007 TB Along the US/Mexico Border El Paso, Texas August 22-23, 2007 International Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007 Barbara J Seaworth MD Medical Director Heartland National

More information

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Lancelot Pinto is a

More information

Let s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Let s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Abstract Nearly 50% of patients with

More information

MODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit

MODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit MODULE SIX Global TB Institutions and Policy Framework Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be Covered Global TB policy and coordinating structures The Stop TB Strategy TB/HIV collaborative

More information

The European Union standards for tuberculosis care: do they need an update?

The European Union standards for tuberculosis care: do they need an update? EDITORIAL EU STANDARDS FOR TB CARE The European Union standards for tuberculosis care: do they need an update? Marieke J. van der Werf 1, Andreas Sandgren 1, Lia D Ambrosio 2, Francesco Blasi 3 and Giovanni

More information

Guidelines for TB contact tracing in Pacific Island countries and territories

Guidelines for TB contact tracing in Pacific Island countries and territories Guidelines for TB contact tracing in Pacific Island countries and territories Background Tuberculosis (TB) continues to be a public health issue of major significance around the world. The World Health

More information

DRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION

DRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION JOURNAL OF PREVENTIVE MEDICINE 2008; 16(3-4): 3-9 Inviting Editorial DRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION Harshad Thakur Centre for Health Policy, Planning and Management,

More information

TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.

TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director. 30 August 2007 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-seventh session Brazzaville, Republic of Congo, 27 31 August Provisional agenda item 7.8 TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE

More information

MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT

MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words

More information

TB: A Supplement to GP CLINICS

TB: A Supplement to GP CLINICS TB: A Supplement to GP CLINICS Chapter 10: Childhood Tuberculosis: Q&A For Primary Care Physicians Author: Madhukar Pai, MD, PhD Author and Series Editor What is Childhood TB and who is at risk? India

More information

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed

More information

Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs

Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs What causes TB? TB is caused by the bacterium Mycobacterium tuberculosis. Although it can cause disease in

More information

Role of RNTCP in the management MDR-TB

Role of RNTCP in the management MDR-TB Kamdar DJ, Shah NA, Patel DJ, Parmarr H. Role of RNTCP in the management of MDR-TB. IAIM, 2015; 2(7): 1-5. Original Research Article Role of RNTCP in the management of MDR-TB Deepali J Kamdar 1, Neha A

More information

Definitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013

Definitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf

More information

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE) TB IN EMERGENCIES Department of Epidemic and Pandemic Alert and Response (EPR) Health Security and Environment Cluster (HSE) (Acknowledgements WHO Stop TB Programme WHO/STB) 1 Why TB? >33% of the global

More information

Tuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012

Tuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis New TB diagnostics. New drugs.new vaccines Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis (TB )is a bacterial disease caused by Mycobacterium tuberculosis (occasionally

More information

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis

More information

Response to Treatment in Sputum Smear Positive Pulmonary Tuberculosis Patients In relation to Human Immunodeficiency Virus in Kano, Nigeria.

Response to Treatment in Sputum Smear Positive Pulmonary Tuberculosis Patients In relation to Human Immunodeficiency Virus in Kano, Nigeria. Response to Treatment in Sputum Smear Positive Pulmonary Tuberculosis Patients In relation to Human Immunodeficiency Virus in Kano, Nigeria. Yusuf Mohammed, Mukhtar Dauda, Ifeanyi Oyeyi TB/HIV Unit, International

More information

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area Rapid communications Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area C Ködmön (csaba.kodmon@ecdc.europa.eu)

More information

TB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012

TB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012 TB & HIV CO-INFECTION IN CHILDREN Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012 Introduction TB & HIV are two of the leading causes of morbidity & mortality in children

More information

GUIDELINES, STATEMENTS & STANDARDS ON TUBERCULOSIS [AS OF FEBRUARY 2005] PART I. GROUPED BY AGENCY/ORGANIZATION

GUIDELINES, STATEMENTS & STANDARDS ON TUBERCULOSIS [AS OF FEBRUARY 2005] PART I. GROUPED BY AGENCY/ORGANIZATION GUIDELINES, STATEMENTS & STANDARDS ON TUBERCULOSIS [AS OF FEBRUARY 2005] PART I. GROUPED BY AGENCY/ORGANIZATION Agency/Organization Name of the Guide/Statement Available at World Health Organization 1

More information

IMPACT OF IMPROVED TREATMENT SUCCESS ON THE PREVALENCE OF TB IN A RURAL COMMUNITY BASED ON ACTIVE SURVEILLANCE

IMPACT OF IMPROVED TREATMENT SUCCESS ON THE PREVALENCE OF TB IN A RURAL COMMUNITY BASED ON ACTIVE SURVEILLANCE Original Article IMPACT OF IMPROVED TREATMENT SUCCESS ON THE PREVALENCE OF TB IN A RURAL COMMUNITY BASED ON ACTIVE SURVEILLANCE P. G. Gopi, R. Subramani, V. Chandrasekaran, T. Santha and P. R. Narayanan

More information

Treatment of Active Tuberculosis

Treatment of Active Tuberculosis Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest

More information

Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite

Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite Riga East Clinical hospital, Centre for tuberculosis and lung diseases. Head of outpatient department.

More information

Research Article. The Epidemiological findings of a 5-Year study on Tuberculosis in the Khuzestan Province during 2008 to 2012

Research Article. The Epidemiological findings of a 5-Year study on Tuberculosis in the Khuzestan Province during 2008 to 2012 Available online www.ijpras.com International Journal of Pharmaceutical Research & Allied Sciences, 2016, 5(2):183-189 Research Article ISSN : 2277-3657 CODEN(USA) : IJPRPM The Epidemiological findings

More information

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe

More information

Controlling TB in the era of HIV

Controlling TB in the era of HIV Controlling TB in the era of HIV Christy Hanson, PhD, MPH TB Research Advisor Amy Bloom, MD TB/HIV Advisor TB Incidence rates highest in Africa Estimated new TB cases (all forms) per 100 000 population

More information

ANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM

ANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM ANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM The form and content of the explanatory note is to: Inform those responsible for completing the DMR 164 Reporting Form - as to

More information

2016 Annual Tuberculosis Report For Fresno County

2016 Annual Tuberculosis Report For Fresno County 206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis

More information

Yakima Health District BULLETIN

Yakima Health District BULLETIN Yakima Health District BULLETIN Summary Volume 13, Issue 1 February, 2014 Tuberculosis in Yakima County The rate of active tuberculosis (TB) in Yakima County has declined by about two-thirds over the past

More information

Tuberculosis Procedure ICPr016. Table of Contents

Tuberculosis Procedure ICPr016. Table of Contents Tuberculosis Procedure ICPr016 Table of Contents Tuberculosis Procedure ICPr016... 1 What is Tuberculosis?... 2 Any required definitions/explanations... 2 NHFT... 2 Tuberculosis (TB)... 3 Latent TB...

More information

Fundamentals of Tuberculosis (TB)

Fundamentals of Tuberculosis (TB) TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported

More information

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016 Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the

More information

Multidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017

Multidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017 Multidrug-/ rifampicinresistant TB (MDR/RR-TB): Update 2017 The global TB situation (1) Estimated incidence, 2016 Estimated number of deaths, 2016 All forms of TB HIV-associated TB Multidrug- / rifampicin-resistant

More information

Annual surveillance report 2015

Annual surveillance report 2015 Annual surveillance report 215 Acknowledgements The Public Health Agency Northern Ireland gratefully acknowledges all those who contributed to this report, including; physicians, nurses, microbiologists,

More information

TUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION In the WHO Western Pacific Region 2002 Report

TUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION In the WHO Western Pacific Region 2002 Report TUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION 2000 Tuberculosis Control In the WHO Western Pacific Region 2002 Report World Health Organization Office for the Western Pacific Region iii TUBERCULOSIS

More information

Predicting outcomes and drug resistance with standardised treatment of active tuberculosis

Predicting outcomes and drug resistance with standardised treatment of active tuberculosis Eur Respir J 21; 36: 87 877 DOI: 1.1183/931936.15179 CopyrightßERS 21 Predicting outcomes and drug resistance with standardised treatment of active tuberculosis O. Oxlade*,#, K. Schwartzman*,#, M. Pai*,#,

More information

Latent tuberculosis infection

Latent tuberculosis infection EXECUTIVE SUMMARY Latent tuberculosis infection Updated and consolidated guidelines for programmatic management Executive summary Latent tuberculosis infection (LTBI) is defined as a state of persistent

More information

Communicable Disease Control Manual Chapter 4: Tuberculosis

Communicable Disease Control Manual Chapter 4: Tuberculosis Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from

More information

GUIDELINES, STATEMENTS & STANDARDS ON TUBERCULOSIS [AS OF NOVEMBER 2004] PART I. GROUPED BY AGENCY/ORGANIZATION

GUIDELINES, STATEMENTS & STANDARDS ON TUBERCULOSIS [AS OF NOVEMBER 2004] PART I. GROUPED BY AGENCY/ORGANIZATION GUIDELINES, STATEMENTS & STANDARDS ON TUBERCULOSIS [AS OF NOVEMBER 2004] PART I. GROUPED BY AGENCY/ORGANIZATION Agency/Organization Name of the Guide/Statement Available at World Health Organization 1

More information

Global, National, Regional

Global, National, Regional Epidemiology of TB: Global, National, Regional September 13, 211 Edward Zuroweste, MD Chief Medical Officer Migrant Clinicians Network Assistant Professor of Medicine Johns Hopkins School of Medicine Epidemiology

More information

Tuberculosis - clinical forms. Dr. A.Torossian,, M.D., Ph. D. Department of Respiratory Diseases

Tuberculosis - clinical forms. Dr. A.Torossian,, M.D., Ph. D. Department of Respiratory Diseases Tuberculosis - clinical forms Dr. A.Torossian,, M.D., Ph. D. Department of Respiratory Diseases 1 TB DISEASE Primary Post-primary (Secondary) Common primary forms Primary complex Tuberculosis of the intrathoracic

More information

TB the basics. (Dr) Margaret (DHA) and John (INZ)

TB the basics. (Dr) Margaret (DHA) and John (INZ) TB the basics (Dr) Margaret (DHA) and John (INZ) Question 1 The scientist who discovered M. tuberculosis was: A: Louis Pasteur B: Robert Koch C: Jean-Antoine Villemin D: Calmette and Guerin Question 2

More information

Int.J.Curr.Microbiol.App.Sci (2015) 4(9):

Int.J.Curr.Microbiol.App.Sci (2015) 4(9): ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 744-748 http://www.ijcmas.com Original Research Article Prevalence of HIV-TB Co-Infection and Study of its Epidemiological Variant among Patient s Attending

More information

Communicable Disease Control Manual Chapter 4: Tuberculosis. Assessment and Follow-Up of TB Contacts

Communicable Disease Control Manual Chapter 4: Tuberculosis. Assessment and Follow-Up of TB Contacts Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Assessment and Follow-Up of TB July, 2018 Page 1 TABLE OF CONTENTS 8.0 ASSESSMENT AND

More information

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin

More information

2010 global TB trends, goals How DOTS happens at country level - an exercise New strategies to address impediments Local challenges

2010 global TB trends, goals How DOTS happens at country level - an exercise New strategies to address impediments Local challenges Outline of what it will take Tuberculosis Elimination 25: Global and Local Challenges Anne Fanning, MD November 9, 211 21 global TB trends, goals How DOTS happens at country level - an exercise New strategies

More information

Clinical aspects of tuberculosis with directly observed treatment in Mehsana district India

Clinical aspects of tuberculosis with directly observed treatment in Mehsana district India ISPUB.COM The Internet Journal of Health Volume 5 Number 2 Clinical aspects of tuberculosis with directly observed treatment in Mehsana district India P Shailesh, C Ankita, P Asha, P Chaganbhai Citation

More information

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female % San Joaquin County (SJC) in 03, (N=43) County Rate = 6. Cases per 00,000 Population I. Demographic Information Table I-A: TB cases by gender, SJC, 03 (N=43) GENDER NUMBER OF CASES Male 6 60.5% Female 7

More information

CMH Working Paper Series

CMH Working Paper Series CMH Working Paper Series Paper No. WG5 : 8 Title Interventions to reduce tuberculosis mortality and transmission in low and middle-income countries: effectiveness, cost-effectiveness, and constraints to

More information

Kenya Perspectives. Post-2015 Development Agenda. Tuberculosis

Kenya Perspectives. Post-2015 Development Agenda. Tuberculosis Kenya Perspectives Post-2015 Development Agenda Tuberculosis SPEAKERS Anna Vassall Anna Vassall is Senior Lecturer in Health Economics at the London School of Hygiene and Tropical Medicine. She is a health

More information

Guidance on Matching Funds: Tuberculosis Finding the Missing People with TB

Guidance on Matching Funds: Tuberculosis Finding the Missing People with TB February 2017 Guidance on Matching Funds: Tuberculosis Finding the Missing People with TB 1. Background TB is the leading cause of death by infectious disease, killing 1.8 million people in 2015. Each

More information

Authors Malhotra, S; Zodpey, S P; Chandra, S; Vashist, R P; Satyanaryana, S; Zachariah, R; Harries, A D

Authors Malhotra, S; Zodpey, S P; Chandra, S; Vashist, R P; Satyanaryana, S; Zachariah, R; Harries, A D MSF Field Research Should Sputum Smear Examination Be Carried Out at the End of the Intensive Phase and End of Treatment in Sputum Smear Negative Pulmonary TB Patients? Authors Malhotra, S; Zodpey, S P;

More information

Principle of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos

Principle of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos Principle of Tuberculosis Control CHIANG Chen-Yuan MD, MPH, DrPhilos Estimated global tuberculosis burden 2015 an estimated 10.4 million incident cases of TB (range, 8.7 million 12.2 million) 142 cases

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Recommendations and Reports June 20, 2003 / 52(RR11);1-77 Recommendations and Reports June 20, 2003 / 52(RR11);1-77 Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society

More information

Global, National, Regional

Global, National, Regional Epidemiology of TB: Global, National, Regional September 13, 211 Edward Zuroweste, MD Chief Medical Officer Migrant Clinicians Network Assistant Professor of Medicine Johns Hopkins School of Medicine Epidemiology

More information

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

TUBERCULOSIS. Presented By: Public Health Madison & Dane County TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any

More information

Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics

Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Neel R. Gandhi, MD Emory Rollins School of Public Health January 17, 2013 Medical Research Council BMJ 1948

More information

Tuberculosis Epidemiology

Tuberculosis Epidemiology Tuberculosis Epidemiology TB CLINICAL INTENSIVE COURSE Curry International Tuberculosis Center October 18, 2017 Varsha Hampole, MPH Tuberculosis Control Branch California Department Of Public Health Outline

More information

The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America

The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America Mike Segar / Reuters Executive Summary Context On 26 September 2018, the United Nations

More information

Annual surveillance report 2016

Annual surveillance report 2016 Annual surveillance report 216 Acknowledgements The Public Health Agency Northern Ireland gratefully acknowledges all those who contributed to this report, including; physicians, nurses, microbiologists,

More information

Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.

Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Principal Investigator: Dick Menzies, MD Evidence base for treatment of INH resistant

More information

TB Clinical Guidelines: Revision Highlights March 2014

TB Clinical Guidelines: Revision Highlights March 2014 TB Clinical Guidelines: Revision Highlights March 2014 AIR TRAVEL & TB CONTROL With respect to non-ambulance air travel of patients diagnosed with or suspected as having active Mycobacterium tuberculosis,

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society of America Please note: An erratum has been published for this article. To view the erratum, please click here.

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research  ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Short Communication Awareness of Medical Interns Regarding Recent Guidelines of Revised National Tuberculosis Control

More information

TUBERCULOSIS CONTACT INVESTIGATION

TUBERCULOSIS CONTACT INVESTIGATION TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE TUBERCULOSIS CONTACT INVESTIGATION LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1. Describe the criteria used

More information

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either

More information

CDC IMMIGRATION REQUIREMENTS:

CDC IMMIGRATION REQUIREMENTS: CDC IMMIGRATION REQUIREMENTS: Technical Instructions for Tuberculosis Screening and Treatment Using Cultures and Directly Observed Therapy October 1, 2009 Table of Contents Preface...i Tuberculosis Screening...1

More information

RAPID DIAGNOSIS AND TREATMENT OF MDR-TB

RAPID DIAGNOSIS AND TREATMENT OF MDR-TB RAPID DIAGNOSIS AND TREATMENT OF MDR-TB FORMING PARTNERSHIPS TO STRENGTHEN THE GLOBAL RESPONSE TO MDR-TB - WHERE IT MATTERS MOST I am delighted that this initiative will improve both the technology needed

More information

Overview of the Presentation

Overview of the Presentation Overview of the Presentation Definitions(TBCase, MDR-TB & XDR-TB) Global Tuberculosis (TB,HIV/TB,MDR & XDR)Scenario & Trend Risk factor for TB Natural history of TB Types of TB & Trends of Extra Pulmonary

More information

TB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research

TB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor

Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor Global scenario*: Burden of TB Incidence : 9.6 million (58% SEAR and Western Pacific) Deaths : 1.5 million

More information

TB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director

TB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director TB 2015 burden, challenges, response Dr Mario RAVIGLIONE Director Addis Ababa, Ethiopia 11-13 November 2015 Overview TB basics TB burden & challenges Response: End TB Strategy DAY 1 What is TB? Definition

More information

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012 TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release

More information

INTENSIFIED TB CASE FINDING

INTENSIFIED TB CASE FINDING INTENSIFIED TB CASE FINDING My friends call me Intensified Case Finding (ICF) I undertake regularly screening all people with, or at high risk of HIV, for symptoms of TB in health care facilities, communities

More information

Tuberculosis in Chicago 2007

Tuberculosis in Chicago 2007 City of Chicago Communicable Disease Information Department of Public Health Richard M. Daley, Mayor May 2008 Terry Mason, MD, FACS, Commissioner www.cityofchicago.org/health/ West Side Center For Disease

More information

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI: Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global

More information

Assessing the programmatic management of drug-resistant TB

Assessing the programmatic management of drug-resistant TB Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many

More information

in South Africa. Authors Coetzee, D; Hilderbrand, K; Goemaere, E; Matthys, F; Boelaert, M /j x

in South Africa. Authors Coetzee, D; Hilderbrand, K; Goemaere, E; Matthys, F; Boelaert, M /j x MSF Field Research Integrating tuberculosis and HIV care in the primary care setting in South Africa. Authors Coetzee, D; Hilderbrand, K; Goemaere, E; Matthys, F; Boelaert, M Citation DOI Journal Rights

More information

Epidemiology of tuberculosis in Northern Ireland. Annual surveillance report 2007

Epidemiology of tuberculosis in Northern Ireland. Annual surveillance report 2007 Epidemiology of tuberculosis in Northern Ireland Annual surveillance report 27 Epidemiology of tuberculosis in Northern Ireland Annual surveillance report 27 Epidemiology of tuberculosis in Northern Ireland:

More information

World Journal of Pharmaceutical and Life Sciences WJPLS

World Journal of Pharmaceutical and Life Sciences WJPLS wjpls, 2019, Vol. 5, Issue 2, 01-06 Research Article ISSN 2454-2229 WJPLS www.wjpls.org SJIF Impact Factor: 5.008 COMPARATIVE STUDY BETWEEN GENEXPERT MTB/RIF ASSAY AND DIRECT SMEAR MICROSCOPY(DSM) FOR

More information

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012 Research Methods for TB Diagnostics Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012 Overview Why do we need good TB diagnostics? What works? What doesn t work? How

More information

Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis

Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis Editorial Optimizing sputum smear microscopy for the diagnosis of pulmonary tuberculosis Sputum smear microscopy has high specificity in tuberculosis-endemic countries, but modest sensitivity that varies

More information

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS The Laboratory s Role in Caring for Patients Diagnosed with TB Frances Morgan, PhD October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE

More information

Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan

Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan Journal of Basic & Applied Sciences, 2018, 14, 107-112 107 Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan Sana Saeed 1, Moosa Raza

More information

Chapter 5 Treatment for Latent Tuberculosis Infection

Chapter 5 Treatment for Latent Tuberculosis Infection Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI

More information

Diagnosis of drug resistant TB

Diagnosis of drug resistant TB Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million

More information

TOG The Way Forward

TOG The Way Forward TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till

More information

PREVALENCE OF HIV INFECTION AND RISK FACTORS OF TUBERCULIN INFECTION AMONG HOUSEHOLD CONTACTS IN AN HIV EPIDEMIC AREA: CHIANG RAI PROVINCE, THAILAND

PREVALENCE OF HIV INFECTION AND RISK FACTORS OF TUBERCULIN INFECTION AMONG HOUSEHOLD CONTACTS IN AN HIV EPIDEMIC AREA: CHIANG RAI PROVINCE, THAILAND JOURNAL OF SCIENCE, Hue University, N 0 61, 2010 PREVALENCE OF HIV INFECTION AND RISK FACTORS OF TUBERCULIN INFECTION AMONG HOUSEHOLD CONTACTS IN AN HIV EPIDEMIC AREA: CHIANG RAI PROVINCE, THAILAND Pornnapa

More information

XDR-TB Extensively Drug-Resistant Tuberculosis. What, Where, How and Action Steps

XDR-TB Extensively Drug-Resistant Tuberculosis. What, Where, How and Action Steps XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever

More information

Active community surveillance of the impact of different tuberculosis control measures, Tiruvallur, South India,

Active community surveillance of the impact of different tuberculosis control measures, Tiruvallur, South India, Int. J. Epidemiol. Advance Access published October 9, 2006 Published by Oxford University Press on behalf of the International Epidemiological Association Ó The Author 2006; all rights reserved. International

More information

TB in Children. Rene De Gama Block 10 Lectures 2012

TB in Children. Rene De Gama Block 10 Lectures 2012 TB in Children Rene De Gama Block 10 Lectures 2012 Contents Epidemiology Transmission and pathogenesis Diagnosis of TB TB and HIV Management Epidemiology The year 2000 8.3 million new TB cases diagnosed

More information

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Who Should Be Screened for Latent Tuberculosis Infection (LTBI)?... 2 What tests are used to screen for LTBI?... 2 How

More information

Addressing TB in a High HIV Prevalence Setting in Rural South Africa: the 3Is

Addressing TB in a High HIV Prevalence Setting in Rural South Africa: the 3Is Addressing TB in a High HIV Prevalence Setting in Rural South Africa: the 3Is Yale AIDS Program Section of Infectious Diseases Yale University School of Medicine Sheela Shenoi MD MPH September 20, 2012

More information

Diagnosis and Treatment of Tuberculosis, 2011

Diagnosis and Treatment of Tuberculosis, 2011 Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is

More information

Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation

Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB Global Consultation Geneva, 30 November 2010 Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva,

More information

HIV and TB Co-infection. Marsh Gelbart

HIV and TB Co-infection. Marsh Gelbart HIV and TB Co-infection Marsh Gelbart 2010 Learning Outcomes To understand that HIV and TB represent the two biggest threats to world public health and in combination are even more deadly To appreciate

More information

CHAPTER 3: DEFINITION OF TERMS

CHAPTER 3: DEFINITION OF TERMS CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria

More information

Asking the Right Questions. A Visual Guide to Tuberculosis Case Management for Nurses. Reference Guide

Asking the Right Questions. A Visual Guide to Tuberculosis Case Management for Nurses. Reference Guide Asking the Right Questions A Visual Guide to Tuberculosis Case Management for Nurses Reference Guide The Francis J. Curry National Tuberculosis Center is a joint project of the San Francisco Department

More information